Frederik De Smet reports on use of the Maxpar Direct Immune Profiling System in the COntAGIouS COVID-19 trial
In this recording, Frederik De Smet, MSc, PhD, presents early data from the COvid-19 Advanced Genetic and Immunologic Sampling (COntAGIouS) clinical research study (NCT04327570) using the Maxpar® Direct™ Immune Profiling Assay™ and Maxpar Pathsetter™ software.
The COntAGIouS trial is a collaboration led by the research university KU Leuven and University Hospital Leuven to perform an in-depth characterization of the dynamic host immune response to coronavirus SARS-CoV-2.
Immune monitoring studies, especially in the age of COVID-19 disease, require cytometry assays that
- are quick to implement with an easy workflow
- have a fixation step early in sample processing
- are high-parameter to ensure the most information possible per cell
- have a streamlined, reproducible and unbiased data analysis pipeline
- have proven reproducibility when performed at multiple sites.
The Maxpar Direct Immune Profiling Assay, designed for use on Helios™, a CyTOF® system, meets all these criteria and helps De Smet’s team observe the different immune system players and their interactions in COVID-19 patient samples.
About the presenter:
Frederik De Smet, MSc, PhD
University of Leuven, Belgium
This webinar first aired on August 5, 2020, at CYTO® 2020.
Contact us to learn more about mass cytometry and the Maxpar Direct Immune Profiling Assay.
For Research Use Only. Not for use in diagnostic procedures.